MSCs-derived HGF alleviates senescence by inhibiting unopposed mitochondrial fusion-based elongation in post-acute kidney injury.
Abstract
The underlying mechanism of human umbilical-derived mesenchymal stem cells (hUC-MSCs) therapy for renal senescence in post-acute kidney injury (post-AKI) remains unclear. Unopposed mitochondrial fusion-based mitochondrial elongation is required for cellular senescence. This study attempted to dissect the role of hUC-MSCs therapy in modulating mitochondrial elongation-related senescence by hUC-MSCs therapy in post-AKI.
The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.
Research summary
The paper investigates the role of hUC-MSCs therapy in modulating mitochondrial elongation-related senescence, which is a mechanism associated with cellular aging. This focus on the underlying mechanisms of senescence in the context of post-acute kidney injury aligns with longevity research. However, the findings appear to be a solid but limited contribution to the field, as they primarily address a specific aspect of cellular senescence without providing broader implications for aging or lifespan extension.
Author of this paper? Send a correction.